A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Phase 1
112
about 6 years
18+
6 sites in FL, OH, TN +1
About this study
Researchers are testing a treatment called BTX-A51 to see if it's safe, how well it works, and what the best dose might be. The trial will involve people with advanced solid tumors or breast cancer. It will happen in three phases: Phase 1a to find the right dose, Phase 1b to see if it works alone, and Phase 1c to test it when combined with another medication.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BTX-A51
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Defining the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of BTX-A51alone and in combination with fulvestrant, Incidence of adverse events after BTX-A51 administration alone and in combination with fulvestrant
Secondary: Duration of response (DoR), Half-life of BTX-A51, Objective response rate (ORR), Overall survival (OS), Progression free survival (PFS)
Oncology